Jun 22, 2020
Therapeutic Solutions International Announces Intention to Use Clinical Stage NK Activating Cancer Immunotherapy for COVID-19
May 12, 2020
Novel CAR NK-cell technology could lead to new treatments for lupus, other incurable diseases
May 06, 2020
Avectas and ONK Therapeutics to Develop Off-the-Shelf Cancer Therapy
Apr 27, 2020
Berkeley Lights Launches Two New Capabilities in the Opto Cell Therapy Development 1.0 Workflow to Accelerate the Creation Of Effective Cancer Immunotherapies
Apr 08, 2020
Avectas Announces Issuance of U.S. Patent for Cell Engineering Technology by the U.S. Patent and Trademark Office
Apr 02, 2020
Seattle's Infectious Disease Research Institute to coordinate the study of a novel COVID-19 treatment
Mar 24, 2020
Avectas and Vycellix Announce Collaboration to Advance Next-Generation Solutions for the Optimized Manufacture of Cell & Gene Therapies
Mar 16, 2020
EnGeneIC Announces Publication in Cancer Cell of a Scientific Paper Highlighting the Ability of EDV(TM) Nanocells to Mount Dual Assault on Cancer Cells
Jan 21, 2020
Berkeley Lights Launches Next Generation B Cell Workflow to Accelerate Therapeutic Antibody Discovery
Jan 10, 2020
Announcement of iPSC Derived Gene-modified NK Cell Development Targeting Solid Tumors
Dec 26, 2019
Astellas Strengthens Immuno-oncology Pipeline with Acquisition of Xyphos Biosciences, Inc.
Aug 20, 2019
NKMax America Initiates Phase I Clinical Trial of SNK in Patients with Psoriasis in Mexico
Aug 15, 2019
Phio Pharmaceuticals and Helmholtz Zentrum München to Collaborate on Novel Targets for the Use of Self-Delivering RNAi In T Cell and NK Cell Adoptive Cell Therapy Therapeutics
Aug 13, 2019
NKMax America Doses First Subject in Phase I Trial of SNK in Patients with Refractory Cancer
Jul 29, 2019
Natural Killer (NK) Cell Therapeutics Market to Reach $5.09 Bn, Globally, by 2026, at 17.4% CAGR: Allied Market Research
Jul 24, 2019
Natural Killer Cell Therapies Pipeline Review 2019
Jun 10, 2019
GT Biopharma Company Update
Apr 24, 2019
GT Biopharma (GTBP) Announces the Elimination of HIV Infected Cells Using its Tri-Specific Killer Engagers (TriKEs) in Preclinical Testing at the University of Minnesota
Feb 01, 2019
Cell Surface Markers - Worldwide Market Analysis & Outlook (2018-2023): The Increasing Funding for Life Science Research is Driving Market Growth
Jan 23, 2019
B-MoGen Biotechnologies and CytoSen Therapeutics partner on research collaboration to develop next generation Natural Killer Cells for human therapeutics